US FDA Appoints Another Orphan Products Development Office Head Amid Growth Expectations
Executive Summary
Janet Maynard will become acting Office of Orphan Products Development director at the end of October, the fourth head of the office in the last 10 months; staff is expected to grow and may begin to provide development advice.
You may also be interested in...
New Translational Science Team Created In US FDA’s CDER To Aid Rare Disease Drug Development
The group is intended to help rare disease drug developers answer all the necessary questions about surrogate endpoints and markers before the application review cycle.
FDA’s New Orphan Products Director Brings Industry, Legal, Academic, Regulatory Background
Sandra Retzky worked at AstraZeneca and in Delaware's Medicaid fraud unit before joining the US FDA in 2016.
US FDA Seeking New Orphan Products Office Director Amid Internal Moves
OOPD’s deputy director has been named the acting head of the office responsible for orphan and rare pediatric disease designations.